Best of ASCO - 2014 Annual Meeting

 

Welcome

Acute Leukemia

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multi-institution comparison of mitoxantrone, etoposide, and cytarabine (MEC) vs. high-dose cytarabine and mitoxantrone (Ara-C Couplets) therapy for patients with relapsed or refractory (R/R) acute myeloid leukemia.

Sonia Christian

e19005

A novel in vitro approach for the identification of exceptional responders in acute myeloid leukemia.

Eric Justin O'Brien

e19011

A phase 1 dose escalation study of the IDH1m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Justin M. Watts

7009

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

Abdul Hamid Bazarbachi

7041

A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).

Guillermo Garcia-Manero

TPS7078

A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.

Mark J. Levis

TPS7075

A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML.

Camille N. Abboud

7043

A retrospective analysis of the impact of antithrombin III supplementation on the incidence of pegaspargase-induced venous thromboembolism.

Jason Chen

e19006

A retrospective study of comorbidities and complications in elderly acute myeloid leukemia (AML) patients in the U.S.

Neil Dhopeshwarkar

7032

AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.

Eytan Stein

TPS7074

All-trans retinoic acid + arsenic trioxide versus other regimens for the treatment of acute promyelocytic leukemia: A single institution experience.

Pritam Tayshetye

e19010

Alterations in serum bilirubin during enasidenib treatment in patients with or without UGT1A1 mutations.

Amir Tahmasb Fathi

e19003

An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

Nicolas Boissel

TPS7076

Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.

Bjorn T. Gjertsen

7020

Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD).

Fevzi Firat Yalniz

7039

Clonal evolution in acute myeloid leukemia (AML): Relapse after a long remission period.

Musa Yilmaz

7022

Comparison of blast clearance in peripheral blood and day 14 bone marrow biopsy for evaluation of disease response after 7+3 induction in acute myeloid leukemia (AML).

Fahrettin Covut

7052

Comparison of somatic mutations profiles from next-generation sequencing (NGS) of cell-free DNA (cfDNA) versus bone marrow (BM) in acute myeloid leukemia (AML).

Rita Elias Assi

7051

CX-01, an inhibitor of CXCL12/CXCR4 axis and of platelet factor 4 (PF4), with azacitidine (AZA) in patients with hypomethylating agent (HMA) refractory AML and MDS.

Eric Huselton

7027

Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.

Mara Rosenberg

7025

Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).

Courtney Denton Dinardo

7010

Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).

Sara Nunnery

e19009

Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.

Ryan Daniel Cassaday

7029

Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells.

Kevin Anthony Hay

7005

Factors influencing first-line therapy of acute myeloid leukemia (AML) patients (pts) in the Connect MDS/AML Disease Registry.

Christopher R. Cogle

7037

Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.

Dietger Niederwieser

7045

First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.

Gautam Borthakur

7019

Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).

Michael Richard Grunwald

7033

iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Leylah Drusbosky

7024

Impact of age on utilization and prognostic value of FLT3 and NPM1 testing in acute myeloid leukemia.

Claudio A Mosse

e19008

Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Elias Jabbour

7013

Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML).

Rita Elias Assi

103

Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation.

Ahmad Ghorab

7023

Impact of remission and stem cell transplant (SCT) on survival outcomes in elderly relapsed acute myeloid leukemia (rAML) patients: US Cancer Registry experience.

Abdalla Aly

e19002

Impact of variant allele frequency of mutant PTPN11 in AML: Single institution experience of 122 patients.

Mansour Alfayez

7046

In acute myeloid leukemia patients CpG-methylation changes associate with resistance to induction chemotherapy.

Christian Dietger Niederwieser

7036

Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.

Jinlin Song

e19000

Initial report of a phase I study of LY2510924 with idarubicin and cytarabine (IA) in relapsed/refractory (R/R) AML.

Prajwal Boddu

7026

Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.

Stefan O. Ciurea

7008

Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).

Anjali S. Advani

7028

Is there a benefit of re-induction therapy in adult patients with AML with <20% blasts?

Kavya Kannamma Kannan

7021

Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.

Daniel Aaron Pollyea

7000

Long-term survival of adults with B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) after treatment with blinatumomab and subsequent allogeneic hematopoietic stem cell transplantation (HSCT).

Max Topp

7044

Low-toxic myeloablative conditioning regimen in haploidentical hematopietic stem cell transplantation for elderly patients with acute myeloid leukemia.

Cynthia Aristei

7038

Molecular testing during AML treatment for early prediction of clinical response.

Hong Yuen Wong

7047

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Courtney Denton Dinardo

7042

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

Tapan M. Kadia

7014

Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).

Tara L. Lin

7040

Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Bijal D. Shah

7006

Outcomes of patients with nucleoplasmin 1 (NPM1) mutated acute myeloid leukemia (AML) treated with hypomethylating agents (HMAs).

Mahesh Swaminathan

7054

Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Wendy Stock

7030

Pharmacodynamic characterization of eryaspase (L-asparaginase encapsulated in red blood cells) in combination with chemotherapy in a phase 2/3 trial in patients with relapsed acute lymphoblastic leukemia (NCT01518517).

Iman El-Hariry

7049

Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.

Bhavana Bhatnagar

7048

Phase 1 trial of pegzilarginase in patients (pts) with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs).

Geoffrey L. Uy

7031

Phase 3 study of first line pevonedistat (PEV) + azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).

Mikkael A. Sekeres

TPS7077

Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid leukemia.

Jorge E. Cortes

TPS7073

Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.

Mark J. Levis

7017

Profiling the immune checkpoint pathway in acute myeloid leukemia.

Paola Dama

7015

Quality of life and psychological distress in patients with acute myeloid leukemia (AML).

Julia Carp

7035

Relapse prevention with second generation tyrosine kinase inhibitors for Ph+ve acute leukemia after allogenic stem cell transplantation.

Faiz K. Anwer

7050

Relationship of minimal residual disease (MRD) in acute lymphocytic leukemia (ALL) and putative leukemia stem cells (LSCs).

Jonathan Michael Gerber

7012

Retrospective analysis of AML patients to identifiy a higher risk of anthracycline-associated cardiac toxicity in Hispanic patients.

Geoffrey Patrick Shouse

e19012

Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML.

Timothy Edward Kubal

e19013

Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.

Melissa L. Larson

7055

Treatment of relapsed/refractory (R/R) B-cell malignancies by chimeric antigen receptor T cells cultured from 50-100 mL peripheral blood in 7-10 days.

Lu Han

7034

Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML.

Patrick Williams

7016

Trial in progress: An open-label, multicenter, phase 3b study to assess the safety and efficacy of midostaurin in patients (pts) aged ≥ 18 y with newly diagnosed (ND) FLT3-mutated acute myeloid leukemia (AML) who are eligible for 7+3 or 5+2 chemotherapy (chemo).

Adolfo Fuentes

TPS7079

Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CAR T cell product.

N. Eric Olson

7007

Validation of the ELN-2017 risk classification in younger adult patients (pts) with AML.

Prajwal Boddu

7053

Venous thrombotic events in Philadelphia chromosome-like acute lymphoblastic leukemia.

Anand Ashwin Patel

e19007